| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Commercialization rights and facilitation services | 118.6 | 100.0 | | | | | | |
| Total neurology product sales, net | 108.1 | 110.3 | 125.3 | | | | | |
| Gralise | 63.1 | 58.1 | 77.0 | | | | | |
| CAMBIA | 32.5 | 35.8 | 31.6 | | | | | |
| Other | | 7.6 | 146.8 | | | | | |
| Total revenues [+] | 229.5 | 311.8 | 380.7 | 455.9 | 342.7 | 390.4 | 134.2 | 90.8 |
| Royalties | | | | | 1.0 | 1.8 | 45.0 | 44.5 |
| Products | | | | | 341.8 | 114.2 | 58.3 | 27.5 |
| License and services | | | | | | 31.5 | 12.8 | 18.8 |
| Revenue growth [+] | -26.4% | -18.1% | -16.5% | 33.0% | -12.2% | 190.9% | 47.8% | -31.7% |
| Commercialization rights and facilitation services | 18.6% | | | | | | | |
| Total neurology product sales, net | -2.0% | -12.0% | | | | | | |
| Gralise | 8.7% | -24.6% | | | | | | |
| CAMBIA | -9.4% | 13.3% | | | | | | |
| Zipsor | -23.7% | -1.9% | | | | | | |
| Cost of goods sold | 9.5 | 18.5 | 72.6 | 87.4 | 67.9 | 15.1 | 7.1 | 6.0 |
| Gross profit | 220.0 | 293.3 | 308.1 | 368.5 | 274.8 | 375.2 | 127.1 | 84.8 |
| Gross margin | 95.9% | 94.1% | 80.9% | 80.8% | 80.2% | 96.1% | 94.7% | 93.4% |
| Selling, general and administrative | 108.9 | 119.2 | 195.7 | 204.5 | 199.4 | 121.1 | 105.2 | 97.6 |
| Research and development | 10.1 | 8.0 | 13.7 | 32.6 | 17.5 | 7.1 | 8.1 | 15.5 |
| Other operating expenses | | -62.0 | -17.1 | 106.8 | 83.3 | 10.2 | | |
| EBITDA [+] | 102.2 | 232.7 | 118.5 | 133.9 | 60.3 | 248.8 | 15.5 | -27.8 |
| EBITDA growth | -56.1% | 96.3% | -11.5% | 121.9% | -75.8% | 1507.7% | -155.7% | -139.1% |
| EBITDA margin | 44.5% | 74.6% | 31.1% | 29.4% | 17.6% | 63.7% | 11.5% | -30.6% |
| Depreciation and amortization | 1.2 | 4.7 | 2.8 | 2.5 | 2.4 | 1.9 | 1.6 | 0.5 |
| EBITA | 101.0 | 228.0 | 115.8 | 131.4 | 57.9 | 247.0 | 13.9 | -28.3 |
| EBITA margin | 44.0% | 73.1% | 30.4% | 28.8% | 16.9% | 63.3% | 10.3% | -31.2% |
| Amortization of intangibles | 101.8 | 101.8 | 102.7 | 106.8 | 83.3 | 10.2 | 4.5 | 2.0 |
| EBIT [+] | -0.7 | 126.3 | 13.0 | 24.5 | -25.4 | 236.8 | 9.3 | -30.4 |
| EBIT growth | -100.6% | 868.9% | -46.8% | -196.5% | -110.7% | 2441.7% | -130.7% | -142.9% |
| EBIT margin | -0.3% | 40.5% | 3.4% | 5.4% | -7.4% | 60.7% | 6.9% | -33.4% |
| Non-recurring items [+] | 193.7 | 82.6 | 55.2 | | 25.0 | | | |
| Asset impairment | 189.8 | | | | | | | |
| Loss (gain) on sale of assets | | | 17.1 | | | | | |
| Legal settlement | | 62.0 | | | -29.9 | | | |
| In-process research & development | | | 24.9 | | 54.9 | | | |
| Interest expense, net [+] | 58.4 | 68.9 | 73.6 | 83.2 | 72.8 | 9.1 | 0.2 | -0.5 |
| Interest expense | 58.4 | 68.9 | 73.6 | 83.7 | 73.4 | 9.3 | 0.9 | 0.0 |
| Interest income | | | | 0.5 | 0.6 | 0.2 | 0.7 | 0.5 |
| Other income (expense), net [+] | 30.3 | 63.2 | 11.8 | -5.8 | | -14.6 | -4.5 | |
| Gain (loss) on debt retirement | 26.4 | | | -5.8 | | | | |
| Other | 3.9 | 1.2 | 0.7 | | | -23.7 | -4.7 | 0.5 |
| Pre-tax income | -222.5 | 38.0 | -103.9 | -64.5 | -123.2 | 213.1 | 4.6 | -29.9 |
| Income taxes | -5.3 | 1.1 | -1.4 | 24.2 | -47.5 | 81.3 | -38.7 | -0.1 |
| Tax rate | 2.4% | 2.8% | 1.4% | | 38.5% | 38.2% | | 0.3% |
| Net income | -217.2 | 36.9 | -102.5 | -88.7 | -75.7 | 131.8 | 43.3 | -29.8 |
| Net margin | -94.6% | 11.8% | -26.9% | -19.5% | -22.1% | 33.8% | 32.3% | -32.8% |
| |
| Basic EPS [+] | ($3.07) | $0.58 | ($1.63) | ($1.45) | ($1.26) | $2.26 | $0.76 | ($0.53) |
| Growth | -630.9% | -135.4% | 12.9% | 14.9% | -155.7% | 196.1% | -243.3% | -141.1% |
| Diluted EPS [+] | ($3.07) | $0.57 | ($1.63) | ($1.45) | ($1.26) | $1.99 | $0.75 | ($0.53) |
| Growth | -634.3% | -135.2% | 12.9% | 14.9% | -163.4% | 164.0% | -241.3% | -142.3% |
| |
| Shares outstanding (basic) [+] | 70.7 | 63.8 | 62.7 | 61.3 | 60.1 | 58.3 | 56.7 | 55.9 |
| Growth | 10.9% | 1.7% | 2.3% | 2.0% | 3.1% | 2.7% | 1.5% | 2.4% |
| Shares outstanding (diluted) [+] | 70.7 | 64.2 | 62.7 | 61.3 | 60.1 | 66.3 | 57.5 | 55.9 |
| Growth | 10.1% | 2.4% | 2.3% | 2.0% | -9.3% | 15.2% | 3.0% | -0.4% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |